☰

Abbott Laboratories

Lower manufacturing cost, wider patient access

Industry
Medical Devices and Diagnostics
Headquarters
Abbott Park, Illinois, United States
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Abbott Laboratories's published strategy and is not endorsed by, or produced in cooperation with, Abbott Laboratories. Company website

Strategic priorities

Abbott has said it wants to reach 3 billion lives a year by 2030, and that the route there runs through the cost of making its products. The CEO describes the goal as bending the cost curve through advanced manufacturing, AI and digitization. The commitment has a near-term number attached: management guided to a 2025 non-GAAP operating margin of 23.5 to 24.0 percent of sales, about 150 basis points above 2024 at the midpoint.

The immediate operational priority sits in Diagnostics. In late 2025 Abbott agreed to acquire Exact Sciences for roughly $21 billion, with closing expected in the second quarter of 2026 and about $100 million of annual synergies targeted by 2028. That means joining a centralized laboratory-service business to one that sells instruments and reagents into other organisations' labs — a data and systems problem as much as a commercial one.

Capacity is being re-shaped at the same time: 35 manufacturing sites across 15 US states, 43 R&D sites, a new cardiovascular device facility in Georgia due for completion in 2028, and a 2030 commitment to cut absolute Scope 1 and 2 emissions by 30 percent from a 2018 baseline. All three lean on the same underlying capability — process and quality data that can be read outside the equipment that produced it.

Challenges we see

  • Quality Manufacturing

    Detecting process deviations while the line is still running

    FreeStyle Libre sensors are made at very high volume and sit inside the fastest-growing part of Abbott's largest segment. In November 2024 Abbott stated that its own internal testing had identified a manufacturing-process issue affecting some sensors, and recalls followed.

    At these volumes the practical expectation is shifting from confirming quality by testing afterwards to reading process signals at the line while a batch is still being made.

  • Data Integration

    Bringing Exact Sciences data into Abbott's diagnostics systems

    Exact Sciences runs a centralized laboratory-service model around Cologuard and Oncotype DX, while Abbott's Core Diagnostics business sells instruments and reagents into other organisations' labs. The transaction is expected to close in the second quarter of 2026.

    The $100 million annual synergy target for 2028 depends on screening, diagnostic and treatment-guidance data moving between two differently-shaped data estates, which makes the integration timetable a data timetable.

  • Operations Manufacturing

    Re-purposing rapid diagnostics capacity for a higher-mix portfolio

    Demand for rapid COVID-19 tests fell sharply, down roughly 75 percent for the rapid diagnostics business by late 2025, and Abbott opened a consultation on its Galway, Ireland rapid diagnostics operation in October 2025.

    Lines and teams configured for one very high-volume product now serve a lower-volume, higher-mix portfolio, which moves changeover time and transferable process knowledge onto the critical path.

  • Compliance Regulatory

    Keeping software validation and security evidence current across connected devices

    Abbott moved Merlin.net Heart Failure Portal data to the cloud in September 2024 and publishes device corrections covering programmer software, including for AVEIR leadless pacemaker systems.

    As more of the portfolio ships with software that can change after release, validation and cybersecurity evidence has to be produced continuously rather than assembled once per product launch.

  • Operations Regulatory

    Producing regulatory and quality documentation across 35 manufacturing sites

    Abbott runs 35 manufacturing sites across 15 US states and 43 R&D sites and sells in more than 160 countries. The FDA closed out its evaluation of corrective actions on infant formula probiotics in December 2024 and continues to monitor sustained compliance, and the 2030 emissions target adds site-level energy reporting on top.

    Documentation and review volume scales with the site and market count, so review capacity rather than the underlying technical work increasingly sets how quickly a change or a release moves.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Reading process signals from sensor lines while the batch runs

    Quality signals from high-volume sensor manufacturing are largely confirmed by testing after the fact. Abbott's own November 2024 statement describes internal testing identifying carbon buildup in the sensor manufacturing process.

    Instrumenting the lines and streaming process data into a monitored model lets a deviation be flagged against a batch that is still on the line, and gives the quality organisation the same view of the process the engineers have.

    • Abbott statement on FreeStyle Libre 3 sensors, November 2024
    • Abbott Reports Fourth-Quarter and Full-Year 2024 Results, 22 January 2025

  2. Putting Abbott and Exact Sciences diagnostics data into one model

    Abbott's diagnostics data comes from instruments installed in other organisations' labs; Exact Sciences' comes from its own centralized laboratory operation. The two describe assays, specimens and results in different structures.

    An agreed ontology for assay, specimen, result, instrument and lot lets both estates load against one model, so the combined data set can be queried once instead of reconciled per report.

    • Abbott to acquire Exact Sciences, press release, 2025
    • Abbott investor presentation, Acquisition of Exact Sciences

  3. Designing IT and OT connectivity for the Georgia facility before it is built

    The new cardiovascular device facility in Georgia is scheduled for completion in 2028. Equipment selection and network design decisions taken now determine for a decade whether plant data is reachable from enterprise systems.

    Setting the protocol standards, network segmentation and equipment data requirements before procurement means interoperability arrives with the machines instead of becoming an integration project after handover.

    • Abbott, Investing in U.S. manufacturing to power health tech

  4. Linking quality control lab results directly to the batch release record

    Where quality control results move between lab systems and the batch record by hand, each transfer is a separate step to perform and to verify, and it sits directly in the release path.

    Capturing results at the instrument and writing them into the batch record as data with their own audit trail shortens the release path and makes the evidence chain readable end to end during an inspection.

    • FDA warning letter close-out, Abbott Laboratories 669353, 12 December 2024
    • Abbott 2024 Annual Report

  5. Shortening the review cycle for regulatory and quality documents

    Deviation reports, change controls, periodic reviews and site sustainability reporting all consume specialist time across dozens of sites, and much of that time goes on assembling and checking documents rather than on the technical judgement inside them.

    Narrow AI agents can draft from source records, check completeness against the template before a document enters the review queue, and find every controlled document a standards change touches, with a named reviewer approving each output.

    • Abbott 2024 Annual Report
    • Abbott 2024 Global Sustainability Report

What we'd propose

  • Digital CDMO

    Real-time process monitoring for device manufacturing lines

    We instrument the production line, bring its process data into one time-series model, and run deviation detection against the batch that is currently running, so a quality signal arrives while the batch is still on the line.

    • Line data acquisition

      Getting data off the equipment

      Connect controllers, sensors and inspection stations through OPC UA (Open Platform Communications Unified Architecture) or MQTT so process values leave the equipment in a documented, vendor-neutral form rather than staying inside a closed controller.

    • Deviation detection against a running batch

      Alerts while the batch runs

      Build the normal operating envelope for each critical process parameter from historical runs, then flag drift against the current batch so operators see a signal in minutes instead of a result in a later report.

    • Automated batch process record

      Evidence assembled as you go

      Write monitored parameters straight into a per-batch record with lineage back to the instrument that produced each value, so the evidence behind a release decision is generated by the line rather than compiled from it.

    • Deviations surface against the batch that is running, not the batch that already shipped.
    • One set of process data serves manufacturing, quality and engineering instead of three separate extracts.
    • Release evidence is produced continuously, so an investigation starts from the record rather than from a reconstruction.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    One data model for Abbott and Exact Sciences diagnostics data

    An ontology-based data platform that defines the entities both businesses share — assay, specimen, result, instrument, lot — once, then loads Abbott's instrument output and Exact Sciences' laboratory-service data against that single model.

    • Shared diagnostics ontology

      One agreed set of terms

      Define assay, specimen, result, instrument and lot as explicit entities with agreed relationships, so a query written once returns comparable answers across both estates instead of two dialects of the same table.

    • Pipelines from instruments and laboratory systems

      Loading both sides

      Build ingestion for Abbott's core laboratory, molecular and point-of-care instrument output and for Exact Sciences' centralized laboratory systems, with schema validation at the boundary so bad records fail loudly instead of silently.

    • Analytics and retrieval on top of the model

      Questions answered without IT tickets

      Expose the model through dashboards and a retrieval layer so commercial, medical and operations teams can ask questions of the combined data set without commissioning a new extract for each one.

    • Integration work is done once against a shared model instead of once per point-to-point interface.
    • Screening, diagnostic and treatment-guidance data can be queried in one place, which is what the published synergy case rests on.
    • New assays and future acquisitions attach to the model rather than triggering another migration.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    IT and OT connectivity design for the new Georgia facility

    An architecture and standards package for the cardiovascular facility due in 2028: network segmentation, protocol choices and equipment data requirements agreed before procurement, so the plant's data path is designed rather than retrofitted.

    • Reference architecture for the plant

      One documented data path

      Specify how equipment, line supervision, manufacturing execution and enterprise systems connect, including the segmentation model, so every vendor on the project builds toward the same target.

    • Equipment data contracts

      What each machine must publish

      Write the OPC UA information models and MQTT topic structures into procurement requirements, making interoperability a purchase condition rather than an integration project after handover.

    • Segmentation and security baseline

      IEC 62443 zones from day one

      Define zones, conduits and remote-access rules to IEC 62443 before commissioning, so the plant's security posture does not have to be re-argued later against a live production line.

    • Interoperability is bought with the equipment instead of built after commissioning.
    • Traceability from raw material to finished device is a property of the design, not a later addition.
    • The same architecture and procurement language is reusable as other US sites are upgraded.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Connecting quality control lab instruments to the batch record

    We integrate the quality control lab's instruments and its LIMS or ELN so results reach the batch record as data carrying their own audit trail, taking transcription and re-keying out of the release path.

    • Instrument integration

      Results captured at source

      Connect balances, analysers and plate readers so results are captured with instrument identity, method version and timestamp attached, instead of being read off a screen and typed into another system.

    • Lab system to batch record data flow

      Lab result to batch record

      Map the lab's sample and result records onto the manufacturing batch record so a release decision can be traced back to the specific analytical run that produced each number.

    • 21 CFR Part 11 audit trail

      Electronic records that hold up

      Implement electronic signature, versioning and audit-trail handling to 21 CFR Part 11, the US rule on electronic records and signatures, so the evidence chain stands on its own during an inspection.

    • Fewer manual transfers between the lab and the batch record, and fewer of them to verify.
    • Inspection questions are answered from the record itself rather than from a reconstruction.
    • Release waits on the analytical result, not on the paperwork that follows it.

    We've done this before

    See how we do Digital Lab
  • Agents

    AI agents for regulatory and quality document work

    Narrow, reviewable agents that take the repetitive part of document work: drafting deviation and change-control summaries from source records, checking a document against its template before review, and finding every controlled document a standards change affects. A named person approves every output.

    • Drafting from source records

      First drafts from system data

      Generate the first draft of a deviation, change-control or periodic-review document directly from the underlying system records, so the author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against its template and the site's own checklist, returning missing or inconsistent sections before it enters the human review queue.

    • Change impact search across the document set

      Which documents a change touches

      When a standard, method or specification changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one.

    • Review queues move faster because documents arrive complete.
    • The scope of a standards change is established by search rather than by recollection.
    • Every output is traceable to the source records it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Abbott Laboratories's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Manufacturing line process data 48 → 82
Abbott runs advanced sites such as Kilkenny, Ireland alongside older lines. The November 2024 sensor statement describes an issue identified by internal testing, which is consistent with quality confirmation resting largely on testing rather than on continuous monitoring at the line.
Data sharing between segments 42 → 78
Four segments carry separate technology estates, and the pending Exact Sciences transaction adds a fifth shape of data. The shared-model work is ahead of the company rather than behind it.
Equipment to enterprise connectivity 52 → 85
Kilkenny shows what a current-generation Abbott site looks like and the 2028 Georgia facility is a chance to set the standard, but 35 US manufacturing sites span several equipment generations.
Software validation and cybersecurity 58 → 84
Enterprise and product cybersecurity sits under the Global CIO, and Merlin.net data moved to the cloud in September 2024. Cloud-hosted patient data and field-updatable device software both raise the bar for continuous validation evidence.
Digital batch records 45 → 80
The FDA's December 2024 close-out on infant formula corrective actions and Abbott's commitment to sustained compliance both favour evidence generated by systems over evidence compiled for review.
Site energy and emissions 38 → 72
The 2030 target of a 30 percent cut in absolute Scope 1 and 2 emissions from a 2018 baseline needs per-site and ideally per-batch energy measurement to be managed during the year rather than reported after it.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Abbott Laboratories, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].